Reviews/Parkinsons Disease Management/Deep brain stimulation improves motor function in advanced Parkinson's
PD DEVICE · PD-03 · v2
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
The studies here agree that stimulating either of two deep-brain targets helps people with long-standing, hard-to-treat Parkinson's move better and cuts the involuntary movements caused by their medication. Several long-term follow-ups, within-person comparisons that switched the device on and off, a randomized study comparing the two targets, and a walking-speed study all point the same way [1][2][3][9]. The reduction in involuntary movements is shown directly, with one long follow-up recording a 75% drop in time spent with those movements [1]. The main caveat is that most of this evidence is observational long-term follow-up rather than a head-to-head test against best drug therapy, and results vary from person to person [8][10]. The panel treated these limits as bounding how broadly the benefit applies rather than as reasons to doubt that the benefit is real.
Motor improvement is demonstrated by within-subject on/off stimulation comparisons [3][4], a randomized target-comparison substudy [2], long-term cohorts [1], and prospective gait kinematics [9], with gait speed rising from 80.6 cm/s at baseline to 97.4 cm/s after activation [9]. Reduction of levodopa-induced dyskinesia is shown directly in [1], where time with dyskinesia fell 75% and off-time fell 58.7%, and is recorded as a maintained long-term benefit in the randomized substudy [2], with GPi antidyskinetic effects localized in [10]. Both targets named in the claim are represented: [2] reports UPDRS-III gains for both GPi and STN, and [9] shows only bilateral STN or GPi improved gait speed. The causal on/off designs give direct attribution of motor benefit to stimulation [3][4]. The contested point: The evidence divides on how uniform and how controlled the benefit is: most efficacy data are uncontrolled long-term follow-up with no comparison against best medical therapy, and the one randomized study [2] has severe attrition and reports quality-of-life and cognitive decline. Outcomes are also heterogeneous, with roughly half of one cohort failing to reach clinically meaningful motor improvement [8] and GPi targeting that 'sometimes fails or worsens' dyskinesia [10].
All 10 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Parkinsons Disease Management, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
Most efficacy evidence is uncontrolled observational follow-up ([1] is explicitly Class IV); the corpus has no comparison against best medical therapy, so absolute efficacy rests partly on within-subject on/off designs with small Ns ([3] N=11, [4] N=19).
The one randomized study [2] has severe attrition (156 enrolled to 49 GPi/28 STN at 10 years) and reports non-motor and quality-of-life decline — benefit is specific to motor/dyskinesia and should not be overread as global benefit.
Where it remains uncertain. Most efficacy evidence is uncontrolled observational follow-up with no best-medical-therapy comparator, and outcomes vary [8][10], so 'substantially' describes an average effect, not a universal one.
Aleatory
Roughly half of one cohort did not reach clinically meaningful motor improvement [8], and GPi targeting sometimes fails or worsens dyskinesia [10], so the effect is an average across a variable response.
Epistemic
The corpus has no comparison against best medical therapy or sham; efficacy rests on observational follow-up and small on/off designs ([3] N=11, [4] N=19).
Inferential
[2] reports maintained motor and dyskinesia benefit but declining quality-of-life and worsening cognition, so the result should not be generalized to global benefit.
The load-bearing papers from a corpus of 10, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Quantifies large long-term reduction in dyskinesia and off-time after STN-DBS — direct support for both the motor-complication and dyskinesia limbs.
“the time spent with dyskinesia and the time spent in the "off" state were reduced by 75% ( p < 0.001) and by 58.7% ( p < 0.001), respectively”
Panel auditInternal validity: low · scope of inference: Patients with PD surviving and retaining STN-DBS beyond 15 years at a single centre; speaks to durability of motor-complication benefit, not to a sham-controlled effect.Key limitations: retrospective single-arm · no control group · survivor cohort · single centre
Randomized-trial substudy establishing motor and dyskinesia benefit for both STN and GPi targets over 10 years.
“DBS therapy has a significant beneficial effect on overall motor function, dyskinesia, and motor fluctuations over 10 years (regardless of target)”
Panel auditInternal validity: high · scope of inference: Patients from the VA/NINDS CSP468 randomized cohort followed to 10 years; speaks to long-term motor and dyskinesia benefit for both STN and GPi, with the caveat that bradykinesia, axial and QoL gains attenuated.Key limitations: heavy attrition by 10 years · some motor timepoints non-significant · non-motor symptoms progressed
Within-subject on/off stimulation contrast causally attributing a large motor improvement to STN stimulation.
“Patients showed a significant improvement in motor symptoms both in the off-medication and on-medication state by a 54% reduction (off-medication/on-stimulation vs. off-medication/off-stimulation)”
Panel auditInternal validity: low · scope of inference: Early-onset PD patients on long-term bilateral STN-DBS, acute stimulation effect on appendicular and axial motor symptoms; does not speak to dyskinesia.Key limitations: n=11 · early-onset subgroup only · acute ON/OFF only · no dyskinesia outcome
The abstract reports preoperative predictors of motor response and a <25% MDS-UPDRS III reduction threshold for loss of benefit, but gives no overall effect size or dyskinesia result to read a direction from.
Panel auditInternal validity: medium · scope of inference: Preoperative clinical/imaging predictors of long-term motor response to bilateral STN-DBS in a large single-centre cohort; it does not quantify whether DBS substantially improves motor function or dyskinesia.Key limitations: predictor study not effect study · no overall effect size · no dyskinesia outcome · single centre
4 of 10 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
The corpus directly and consistently supports both the motor and dyskinesia limbs across both targets with causal on/off and one randomized design, placing it just inside the Established band.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No comparison against best medical therapy. Without a controlled contrast, the size of the stimulation benefit over optimized drug therapy cannot be isolated from disease course or care. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A randomized trial of DBS plus medical therapy versus best medical therapy alone with blinded motor and dyskinesia outcomes.
Open question: How large is the motor and dyskinesia benefit of DBS relative to continued best medical therapy? Why it is still open: The corpus has no best-medical-therapy or sham comparator; efficacy is inferred from within-subject switching and follow-up [1][3][4].
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19